Annual report pursuant to Section 13 and 15(d)

Acquisitions (Details)

v3.22.2
Acquisitions (Details) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Dec. 18, 2020
Dec. 31, 2021
Dec. 31, 2020
Jan. 03, 2020
Business Acquisition [Line Items]        
Share Price       $ 10.00
Panoptes        
Business Acquisition [Line Items]        
Percentage of equity interests acquired 100.00%      
Cash consideration paid $ 445      
Fair value of contingent consideration     $ 1,353  
Fair value of shares issued $ 3,169      
Threshold period of volume weighted average price 30 days      
Volume weighted average price $ 3.5321      
Holdback Shares $ 1,500      
Panoptes | Due to creditor        
Business Acquisition [Line Items]        
Fair Value at the acquisition date   $ 212    
Panoptes | Milestone payments        
Business Acquisition [Line Items]        
Fair value of contingent consideration $ 2,280      
Panoptes | 18-month Period subject to post-closing adjustments        
Business Acquisition [Line Items]        
Shares issued as consideration 1,500      
Number of shares convertible 424,685      
Panoptes | If milestone payments are exercised for shares | Minimum        
Business Acquisition [Line Items]        
Share Price $ 2.4725      
Panoptes | If milestone payments are exercised for shares | Maximum        
Business Acquisition [Line Items]        
Share Price $ 4.5917      
Panoptes | Upon the enrollment and randomization of a first patient into the first FDA Phase III pivotal study of a Panoptes product        
Business Acquisition [Line Items]        
Milestone payments in cash or stock $ 4,750      
Panoptes | Upon the FDA approval of the first New Drug Application of a Panoptes product        
Business Acquisition [Line Items]        
Milestone payments in cash or stock $ 4,750      
Bayon        
Business Acquisition [Line Items]        
Percentage of equity interests acquired   100.00%    
Cash consideration paid   $ 97    
Shares issued as consideration   33,798    
Fair value of shares issued   $ 68    
Volume weighted average price   $ 2.01    
Bayon | Due to creditor        
Business Acquisition [Line Items]        
Fair Value at the acquisition date   $ 1,008    
Bayon | Earn-out provisions        
Business Acquisition [Line Items]        
Earnout consideration   $ 7,135    
Bayon | If milestone payments are exercised for shares | Phase 1b milestones        
Business Acquisition [Line Items]        
Share Price   $ 2.01    
Bayon | If milestone payments are exercised for shares | Remaining milestones        
Business Acquisition [Line Items]        
Share Price   $ 3.30    
Common Stock | Panoptes        
Business Acquisition [Line Items]        
Shares issued as consideration 884,222      
Series D Convertible Preferred Stock | Panoptes        
Business Acquisition [Line Items]        
Shares issued as consideration 45.893      
Number of shares convertible 13,000